Amicus Therapeutics (FOLD) CEO disposes 1.0M shares, options in BioMarin merger
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Amicus Therapeutics President and CEO Bradley L. Campbell reported the disposition of his equity interests in connection with the acquisition of Amicus by BioMarin Pharmaceutical. The filing shows 1,008,680 shares of Common Stock were disposed of, consisting of 689,467 shares and 319,213 restricted stock units that vested in full at closing of the merger.
The Form 4 also reports multiple stock option awards being disposed of to the issuer. Each option was cancelled at the merger closing and converted into a cash right equal to the excess of the $14.50 per share merger price over its exercise price, multiplied by the number of option shares. Following these transactions, the reported common shares and these options show zero remaining direct holdings.
Positive
- None.
Negative
- None.
Insider Trade Summary
9 transactions reported
Mixed
9 txns
Insider
Campbell Bradley L
Role
President and CEO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Options (right to buy) | 103,578 | $0.00 | -- |
| Disposition | Stock Options (right to buy) | 151,515 | $0.00 | -- |
| Disposition | Stock Options (right to buy) | 188,257 | $0.00 | -- |
| Disposition | Stock Options (right to buy) | 283,555 | $0.00 | -- |
| Disposition | Stock Options (right to buy) | 187,970 | $0.00 | -- |
| Disposition | Stock Options (right to buy) | 301,109 | $0.00 | -- |
| Disposition | Stock Options (right to buy) | 265,517 | $0.00 | -- |
| Disposition | Stock Options (right to buy) | 482,908 | $0.00 | -- |
| Disposition | Common Stock | 1,008,680 | $14.50 | $14.63M |
Holdings After Transaction:
Stock Options (right to buy) — 0 shares (Direct, null);
Common Stock — 0 shares (Direct, null)
Footnotes (1)
- The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 689,467 shares of Common Stock and 319,213 restricted stock units (which vested in full in connection with consummation of the Merger). In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. Each Option was fully vested. Each Option vested in full in connection with consummation of the Merger.
Key Figures
Common shares disposed: 1,008,680 shares
Common shares component: 689,467 shares
Restricted stock units: 319,213 units
+3 more
6 metrics
Common shares disposed
1,008,680 shares
Total Common Stock tied to merger disposition
Common shares component
689,467 shares
Portion of disposed Common Stock (non-RSU)
Restricted stock units
319,213 units
RSUs that vested in full at merger closing
Merger cash reference price
$14.50 per share
Price used to determine option cash-out value
Largest option grant cancelled
482,908 shares
Stock option at $9.41 exercise price
Option exercise prices range
$5.13–$14.24 per share
Exercise prices for reported options cancelled
Key Terms
restricted stock units, stock option, Merger, exercise price, +1 more
5 terms
restricted stock units financial
"which included 689,467 shares of Common Stock and 319,213 restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
stock option financial
"In connection with consummation of the Merger, each reported stock option ("Option") was cancelled"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
Merger financial
"disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger")"
A merger is when two companies combine into a single business, with ownership and control reorganized so they operate as one entity. For investors it matters because mergers can change the value and risk of holdings—shares may be exchanged, diluted, or rise if the combined company saves costs or gains market power, and the deal often depends on regulatory approval and successful integration like two households joining resources and routines.
exercise price financial
"equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
cash payment financial
"was cancelled and converted into the right to receive a cash payment equal to"
FAQ
What insider transaction did Amicus Therapeutics (FOLD) report on this Form 4?
The Form 4 reports Amicus Therapeutics President and CEO Bradley L. Campbell disposing of equity in connection with the BioMarin merger, including 1,008,680 shares of Common Stock and multiple stock option awards that were cancelled and converted into cash rights.
What happened to the Amicus Therapeutics (FOLD) restricted stock units held by the CEO?
The CEO’s 319,213 restricted stock units vested in full when the BioMarin merger closed and were included in the 1,008,680 reported shares disposed of. These units ceased to exist as equity and were treated as part of the merger consideration.
How were the Amicus Therapeutics (FOLD) stock options treated in the BioMarin merger?
Each reported stock option was cancelled at the merger closing and converted into a cash right. The payment equaled $14.50 per share minus the option’s exercise price, multiplied by the number of underlying shares, and each option was fully vested at that time.
Does the Amicus Therapeutics (FOLD) CEO retain these reported options after the merger?
No. The filing shows each reported stock option was cancelled in connection with the merger and turned into a cash entitlement based on the $14.50 per share merger price, leaving zero remaining holdings for these specific options after the transaction.
What exercise prices applied to the Amicus Therapeutics (FOLD) options cancelled in the merger?
The cancelled options covered multiple grants with exercise prices such as $9.41, $14.24, $11.93, $8.95, $12.11, $9.55, $10.04, and $5.13 per share. Each was cashed out based on the $14.50 per share merger price minus its respective exercise price.